Last reviewed · How we verify
NCT06964477: XR-MHLP
A Trial of Extended Reality Activities to Enhance Leisure Participation Among Inpatients With Persistent Mental Health Conditions
NA trial testing XR-Based Leisure Intervention in Schizophrenia and Related Disorders in 25 participants. Not yet recruiting.
15 September 2025
Quick facts
| Lead sponsor | Chia-Hui Hung |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 1 July 2025 |
| Primary completion | 15 September 2025 |
| Estimated completion | 31 October 2025 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- XR-Based Leisure Intervention
Conditions studied
- Schizophrenia and Related Disorders — all drugs for Schizophrenia and Related Disorders →
- Mental Disorders — all drugs for Mental Disorders →
- Inpatients — all drugs for Inpatients →
Sponsor
Chia-Hui Hung
Who can join
Adults 20 to 65, any sex, with Schizophrenia and Related Disorders or Mental Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to evaluate the effects of an extended reality (XR)-enhanced occupational therapy leisure intervention on motivation, emotional engagement, and therapeutic participation among inpatients with chronic psychiatric conditions. The main questions it aims to answer are: Can the XR intervention improve leisure motivation, leisure-related attitudes, and emotional coping strategies in long-term hospitalized individuals with mental illness? Does the XR intervention promote improvements in psychological health, volition, and occupational performance? Researchers will compare an XR-based leisure therapy group to a usual care group engaged in standard hospital leisure activities such as art, music, or reading. Participants will take part in weekly 40-minute sessions for 6 weeks. The XR group will use a custom-designed mobile VR program featuring immersive 360° leisure scenarios aligned with participants' interests and functional goals. Data collection includes standardized assessments (e.g., Interest Checklist, Volitional Questionnaire, COPM, PANSS) and semi-structured interviews to explore changes in motivation, coping, and perceived benefits.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06964477
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia and Related Disorders
Currently open trials in the same condition.
- NCT07378150 — Clay Therapy in Schizophrenia Patients · NA · recruiting
- NCT07119268 — SPARK Healthy Sleep · NA · recruiting
- NCT05603104 — Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First- · Phase 3 · recruiting
- NCT02916810 — Alternative Stimulation Mode and Location for Auditory Hallucination Neuromodulation Treatment · NA · recruiting
- NCT06426134 — Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06964477 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chia-Hui Hung
- Last refreshed: 9 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06964477.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing